1. Impact of atherosclerosis imaging-quantitative computed tomography on diagnostic certainty, downstream testing, coronary revascularization, and medical therapy: the CERTAIN study.
- Author
-
Karlsberg, Ronald, Gupta, Himanshu, Sullenberger, Lance, Quesada, Carlos, Rahban, Habib, Woods, Kevin, Uzzilia, Jeffrey, Purga, Scott, Aquino, Melissa, Hoffmann, Udo, Min, James, Earls, James, Choi, Andrew, Nurmohamed, Nick, Cole, Jason, and Budoff, Matthew
- Subjects
AI-QCT ,CCTA ,artificial intelligence ,atherosclerosis imaging-quantitative computed tomography ,coronary CT angiography ,multi-centre ,Humans ,Male ,Female ,Middle Aged ,Coronary Artery Disease ,Computed Tomography Angiography ,Coronary Angiography ,Prospective Studies ,Aged ,Cross-Over Studies ,Myocardial Revascularization ,Tomography ,X-Ray Computed - Abstract
AIMS: The incremental impact of atherosclerosis imaging-quantitative computed tomography (AI-QCT) on diagnostic certainty and downstream patient management is not yet known. The aim of this study was to compare the clinical utility of the routine implementation of AI-QCT versus conventional visual coronary CT angiography (CCTA) interpretation. METHODS AND RESULTS: In this multi-centre cross-over study in 5 expert CCTA sites, 750 consecutive adult patients referred for CCTA were prospectively recruited. Blinded to the AI-QCT analysis, site physicians established patient diagnoses and plans for downstream non-invasive testing, coronary intervention, and medication management based on the conventional site assessment. Next, physicians were asked to repeat their assessments based upon AI-QCT results. The included patients had an age of 63.8 ± 12.2 years; 433 (57.7%) were male. Compared with the conventional site CCTA evaluation, AI-QCT analysis improved physicians confidence two- to five-fold at every step of the care pathway and was associated with change in diagnosis or management in the majority of patients (428; 57.1%; P < 0.001), including for measures such as Coronary Artery Disease-Reporting and Data System (CAD-RADS) (295; 39.3%; P < 0.001) and plaque burden (197; 26.3%; P < 0.001). After AI-QCT including ischaemia assessment, the need for downstream non-invasive and invasive testing was reduced by 37.1% (P < 0.001), compared with the conventional site CCTA evaluation. Incremental to the site CCTA evaluation alone, AI-QCT resulted in statin initiation/increase an aspirin initiation in an additional 28.1% (P < 0.001) and 23.0% (P < 0.001) of patients, respectively. CONCLUSION: The use of AI-QCT improves diagnostic certainty and may result in reduced downstream need for non-invasive testing and increased rates of preventive medical therapy.
- Published
- 2024